Search results for: 'android ed plan terminal forecast 2025'

02 Sep 2025  |  Global  |  Technology Research

Technological Advances in Engineered Cell Therapies, Global, 2025–2029

Emerging Trends and Technologies in Engineered Cell Therapies

Infographics

×

Engineered cell therapies have become a revolutionary medical field, surpassing conventional methods such as systemic medications and prominent immunosuppression to provide long-lasting, programmable, and targeted treatments for complicated diseases. Recent technical developments in engineered cell therapies examine how the rapid growth of cell eng...

08 Sep 2025  |  Global  |  Market Research

Growth Opportunities in Global Protein and Peptide Therapeutics, Forecast to 2030

Cross-Therapeutic Expansion is Driving Transformational Growth Fueled by Novel Formats and Smarter Delivery

Infographics

×

The protein and peptide therapeutics industry is undergoing a profound transformation, driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and GLP-1 treatments. These advances are intensifying competition, while the patent expiries of blockbuster antibodies are accelerating the entry of biosimi...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

15 May 2025  |  Global  |  Market Research

Immunomodulator Therapeutics Market, Global, 2024–2030

Mechanism-targeted Approaches are Driving Transformational Growth by Enabling Innovation in Autoimmune, Oncology, and Inflammatory Therapies

Infographics

×

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) ...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

19 Apr 2017  |  Asia Pacific  |  Market Research

Global CRO Market, Forecast to 2021

The Global CRO Market to Reach $64.58 Billion by 2021

Infographics

×

The Global CRO Market, Forecast to 2021, presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides revenue forecasts for CROs globally by phase, therapeutic type and region. With the consolidation of the market as well as a higher cost and risk involved, the big companies are slowly shifting ...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...